Bruce Bent - Jun 14, 2022 Form 3 Insider Report for Heart Test Laboratories, Inc. (HSCS)

Role
Director
Signature
/s/ Mark Hilz, Attorney-In-Fact
Stock symbol
HSCS
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
3
Date filed
7/7/2022, 05:21 PM
Previous filing
Aug 16, 2021
Next filing
Mar 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HSCS Common Stock 1.64K Jun 14, 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 1.89K $3.47 Direct F1
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 1.89K $3.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F2 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.